Drugs / YL242
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07197827 | Sep 2025 → Sep 2028 expected | neoplasm | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YL242 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07197827 ↗ |
| Route | Intravenous | “The initial dose of YL242 will be infused IV into each patient” NCT07197827 ↗ |